Background In the demyelinating disease multiple sclerosis (MS), chronic-active brain
inflammation, remyelination failure and neurodegeneration remain major issues despite …

Atrophy related to multiple sclerosis (MS) has been found at the early stages of the disease.
However, the archetype dynamic trajectories of the neurodegenerative process, even prior …

Background: Thalamic volume (TV) is a sensitive biomarker of disease burden of injury in
multiple sclerosis (MS) and appears to reflect overall lesion loads. Ibudilast showed …

Objective To explore longitudinal changes in brain volumetric measures and retinal layer
thicknesses following acute optic neuritis (AON) in people with multiple sclerosis (PwMS), to …

Background We investigated sex-related differences in upper limb motor performance tested
with the 9-Hole Peg Test (9HPT) in healthy controls (HC) and multiple sclerosis (MS) …

Background White matter (WM) lesions and brain atrophy are present early in multiple
sclerosis (MS). However, their spatio-temporal relationship remains unclear. Methods Yearly …

BACKGROUND AND PURPOSE: Thalamic atrophy occurs from the earliest phases of MS;
however, this measure is not included in clinical practice. Our purpose was to obtain a …

Brain atrophy in multiple sclerosis (MS), as measured by percentage brain volume change
(PBVC) from brain magnetic resonance imaging (MRI), has been established as an outcome …

BACKGROUND METHODS RESULTS Page 1 Ublituximab Reduces Thalamic Volume Loss
and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies OBJECTIVE …

Multiple sclerosis (MS) is the most common immune-mediated disease of the central
nervous system. While benign cases exist, if left untreated, MS results in the compounding …